共 79 条
[1]
Esmon CT(1992)The protein C anticoagulant pathway. Arterioscler Thromb 12 135-145
[2]
Walker FJ(1979)The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V. Biochim Biophys Acta 571 333-342
[3]
Sexton PW(1984)Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V [abstract]. Blood 63 486-489
[4]
Esmon CT(2001)The Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group, Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 699-709
[5]
Fulcher CA(2001)Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 29 2051-2059
[6]
Gardiner JE(2001)Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29 1303-1310
[7]
Griffin JH(2001)Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, does escalation study. Crit Care Med 29 2081-2089
[8]
Zimmerman TS(2001)Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286 1869-1878
[9]
Bernard GR(2002)Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin Pharmacol Ther 72 391-402
[10]
Vincent J-L(1999)Spontaneous intracerebral hemorrhage in critically ill patients: incidence over six years and associated factors. Intensive Care Med 25 63-67